How HemoDiff Improves Hematology Diagnostics: Key Benefits and Uses

HemoDiff vs. Traditional CBC: When to Choose Automated Differential Analysis

Traditional CBC (central lab automated CBC + manual smear review): High-throughput analyzers (e.g., Sysmex, Beckman Coulter) perform CBC and pre-classify WBCs; abnormal/flagged samples are reflex-reviewed manually by a technologist.
HemoDiff (point‑of‑care / compact automated differential, e.g., HemoScreen/HemoDiff-type devices): Smaller, often image‑ or AI‑assisted analyzers that provide CBC with an automated 3‑ or 5‑part WBC differential at or near the patient, designed for fast results and fewer false flags in many routine samples.

Speed: Results available during the visit — useful for emergency, outpatient or bedside decision-making.
Workflow: Reduces specimen transport and lab turnaround; fewer samples need manual review when flag specificity is high.
Accessibility: Enables testing in small clinics, infusion centers, or remote sites without full lab infrastructure.
Good concordance for common parameters: Studies show strong correlation with central lab analyzers for hemoglobin, WBC, neutrophils, lymphocytes and platelets in non‑abnormal samples.

Lower performance on abnormal/pathologic samples: Automated compact systems can miss or misclassify blasts, immature/atypical cells, severe leukemias, or marked morphologic abnormalities — manual microscopy or high‑end analyzers remain gold standard for these.
Restricted parameter set: Some POC devices provide fewer differential classes or fewer ancillary metrics (reticulocyte indices, NRBC, certain immature granulocyte flags).
Inter-instrument variability: Counts (especially monocytes, basophils, eosinophils, NRBC) can vary between platforms; confirmatory testing may be needed.
Quality control & maintenance: Smaller sites must implement QC and trained operators; abnormal flagging still requires expert review.

Use when:
1. Rapid, on‑site decision-making is required (ED triage, urgent clinic